---
title: "Somatropin (HGH)"
slug: "somatropin"
type: "compound"
category: "Body Composition"
url: "https://peptidesciencethailand.com/compounds/somatropin"
description: "Recombinant human growth hormone with decades of clinical use across multiple approved indications. Mechanism, evidence base, and monitoring requirements."
---
# Somatropin (HGH)

*Recombinant Human Growth Hormone, Direct Somatotropic Axis Supplementation*

**Category:** Body Composition  
**Format:** Auto-Injector Pen  
**Amount:** 50 IU  
**Purity:** >99.0% (HPLC)

## Overview

Somatropin is recombinant human growth hormone (rhGH), a 191-amino acid single-chain polypeptide produced through recombinant DNA technology that is structurally and functionally identical to pituitary-derived human growth hormone. The protein adopts a four-helix bundle topology stabilized by two disulfide bonds (Cys53-Cys165 and Cys182-Cys189), and its biological activity is mediated through binding to the growth hormone receptor (GHR), a type I cytokine receptor expressed on hepatocytes, adipocytes, muscle cells, chondrocytes, and numerous other cell types throughout the body.

Growth hormone signaling through the GHR initiates a complex intracellular cascade beginning with receptor dimerization upon ligand binding. One molecule of GH binds to two GHR molecules through two distinct binding sites (Site 1 and Site 2) on the GH molecule, inducing a conformational change that activates the receptor-associated Janus kinase 2 (JAK2). Activated JAK2 phosphorylates tyrosine residues on the intracellular domain of GHR, creating docking sites for signal transducers and activators of transcription (STAT) proteins, primarily STAT5b. Phosphorylated STAT5b dimerizes and translocates to the nucleus, where it activates transcription of GH-responsive genes, most importantly the gene encoding insulin-like growth factor 1 (IGF-1).

The hepatic production of IGF-1 in response to GH stimulation represents the primary endocrine mediating mechanism of growth hormone's systemic effects. IGF-1 circulates bound to IGF binding proteins (IGFBPs), predominantly IGFBP-3 in complex with the acid-labile subunit (ALS), which extends its half-life from approximately 10 minutes (free IGF-1) to 12-15 hours. IGF-1 signals through the IGF-1 receptor (IGF-1R), a transmembrane tyrosine kinase receptor that activates the PI3K/Akt and MAPK/ERK pathways, promoting cell proliferation, survival, and differentiation across multiple tissue types.

Growth hormone exerts direct metabolic effects independent of IGF-1 production. In adipose tissue, GH stimulates lipolysis through activation of hormone-sensitive lipase (HSL), mobilizing stored triglycerides into free fatty acids and glycerol for oxidative metabolism. This lipolytic effect is one of the most consistent and dose-dependent actions of GH, and it preferentially targets visceral adipose depots over subcutaneous fat stores. Concurrently, GH inhibits lipogenesis and reduces adipose tissue glucose uptake, shifting the metabolic substrate preference toward fatty acid oxidation.

In skeletal muscle, GH promotes protein synthesis through both direct JAK2/STAT5 signaling and indirect IGF-1-mediated PI3K/Akt/mTOR pathway activation. The net effect is increased nitrogen retention and positive protein balance, supporting lean tissue maintenance and development. GH also promotes amino acid transport into muscle cells and enhances ribosomal assembly for protein translation. These anabolic effects are complemented by the anti-catabolic properties of GH, which reduces protein catabolism during caloric restriction or physiological stress.

Bone metabolism is profoundly influenced by growth hormone through both direct and IGF-1-mediated pathways. GH stimulates osteoblast differentiation and activity, promotes chondrocyte proliferation in growth plates (relevant in pediatric applications), and supports the production of type I collagen, the primary structural protein of bone matrix. IGF-1 mediates many of these effects and also stimulates renal production of 1,25-dihydroxyvitamin D, enhancing intestinal calcium absorption and supporting bone mineralization.

Connective tissue remodeling is another significant domain of GH/IGF-1 activity. Collagen synthesis in tendons, ligaments, skin, and cartilage is stimulated by IGF-1, contributing to connective tissue integrity and repair capacity. This effect on collagen has implications for skin thickness and elasticity, joint health, and recovery from musculoskeletal injuries.

The physiological secretion pattern of endogenous GH is pulsatile, with the largest secretory pulse occurring during slow-wave (deep) sleep and additional pulses occurring in response to exercise, fasting, and other stimuli. This pulsatile pattern is regulated by the interplay of growth hormone-releasing hormone (GHRH) from the hypothalamus, which stimulates GH release, and somatostatin, which inhibits it. GH secretion declines with age, a phenomenon termed "somatopause," with mean 24-hour GH secretion declining approximately 14% per decade after age 30.

GH has well-characterized effects on glucose metabolism that require careful monitoring. By promoting lipolysis and fatty acid oxidation, GH induces a state of relative insulin resistance, reducing peripheral glucose uptake. This diabetogenic effect is counterbalanced in healthy individuals by compensatory increases in insulin secretion, but in predisposed individuals, GH administration can unmask or exacerbate impaired glucose tolerance.

The recombinant production of somatropin ensures batch-to-batch consistency with a defined amino acid sequence identical to endogenous human GH. The auto-injector pen delivers 50 IU of somatropin in a pre-mixed format with adjustable dose selection, enabling precise administration without reconstitution requirements.

## Mechanism of Action

### Step 1: GH Receptor Dimerization & JAK2 Activation

Somatropin binds to two growth hormone receptor (GHR) molecules through Sites 1 and 2, inducing receptor dimerization. This conformational change activates receptor-associated Janus kinase 2 (JAK2), initiating the intracellular signaling cascade.

### Step 2: STAT5b Nuclear Translocation

Activated JAK2 phosphorylates GHR intracellular domains, creating docking sites for STAT5b. Phosphorylated STAT5b dimerizes and translocates to the nucleus, activating transcription of GH-responsive genes including IGF-1, the primary endocrine mediator of growth hormone effects.

### Step 3: Hepatic IGF-1 Production & Systemic Distribution

STAT5b-driven hepatic IGF-1 gene expression produces IGF-1, which enters circulation bound to IGFBP-3/ALS complexes. This extends IGF-1 half-life and delivers growth factor signaling to muscle, bone, connective tissue, and other target tissues systemically.

### Step 4: Direct Lipolytic & Metabolic Effects

GH directly activates hormone-sensitive lipase in adipose tissue, mobilizing stored triglycerides for fatty acid oxidation. This lipolytic effect preferentially targets visceral fat depots and shifts whole-body substrate metabolism toward fatty acid utilization.

### Step 5: Anabolic Tissue Building (Muscle, Bone, Collagen)

IGF-1 activates PI3K/Akt/mTOR signaling in skeletal muscle, promoting protein synthesis and nitrogen retention. In bone, osteoblast activation and collagen synthesis support mineralization. Connective tissue collagen production enhances tendon, ligament, and skin integrity.

## Researched Benefits

### Body Composition Optimization

Growth hormone's combined lipolytic and anabolic effects produce favorable shifts in body composition. Research consistently demonstrates reductions in adipose tissue (particularly visceral fat) with simultaneous preservation or increase in lean body mass. These dual effects distinguish GH from interventions that affect only one compartment.

### Connective Tissue & Collagen Support

GH/IGF-1 axis activation stimulates collagen synthesis across multiple connective tissue types including tendons, ligaments, cartilage, and skin. This supports structural integrity, repair capacity, and resilience of the musculoskeletal system, with additional implications for skin thickness and elasticity.

### Bone Mineral Density Maintenance

Through direct osteoblast stimulation and IGF-1-mediated enhancement of calcium metabolism, growth hormone supports bone mineral density. Research in GH-deficient adults demonstrates significant improvements in bone mineral content with GH replacement, particularly notable at cortical bone sites.

### Metabolic & Recovery Support

GH promotes anabolic metabolism, enhances nitrogen retention, and supports tissue repair capacity. The shift toward fatty acid oxidation as a primary fuel source, combined with enhanced protein synthesis and growth factor production, contributes to improved recovery capacity and metabolic resilience.

## Dosage & Administration

| Parameter | Detail |
| --- | --- |
| Protocol | 1-4 IU per day administered subcutaneously, typically in the evening or before sleep. Dose determined by the your specialist based on IGF-1 levels, clinical indication, and metabolic monitoring |
| Route | Subcutaneous injection via auto-injector pen |
| Duration | Ongoing under specialist supervision with regular monitoring. Protocols typically reassess at 3-6 month intervals. |
| Cycle Notes | Growth hormone protocols vary based on indication. Anti-aging and body composition protocols may use 1-2 IU daily continuously, while higher doses for specific conditions require more frequent monitoring. Some protocols incorporate 5 days on / 2 days off schedules, though evidence for cycling benefits is limited. |
| Reconstitution | No reconstitution required. The auto-injector pen contains pre-mixed somatropin solution at 50 IU total capacity with dose-selection dial. Store in refrigerator at 2-8 degrees C. After first use, may be stored at room temperature below 25 degrees C for up to 4 weeks. Protect from light. |

> **Specialist note:** Somatropin administration requires comprehensive baseline evaluation including IGF-1, fasting glucose, HbA1c, insulin, lipid panel, thyroid function (GH can increase T4-to-T3 conversion), and screening for active malignancies or proliferative retinopathy. Regular monitoring at 4-12 week intervals is essential. Dose titration targets IGF-1 levels within the upper-normal age-adjusted reference range.

## Compound Reference Data

| Property | Value |
| --- | --- |
| Format | Pre-filled Auto-Injector Pen |
| Amount | 50 IU per pen (approximately 16.7mg) |
| Purity | >99.0% |
| Purity Method | HPLC and SEC (Size Exclusion Chromatography) |
| Sequence | 191-amino acid single-chain polypeptide identical to endogenous human GH (four-helix bundle, two disulfide bonds: Cys53-Cys165, Cys182-Cys189) |
| Molecular Weight | 22,124 g/mol |
| Storage | Store unused pen refrigerated at 2-8 degrees C. After first use, store at room temperature below 25 degrees C for up to 4 weeks or refrigerated. Do not freeze. Protect from light. |
| Appearance | Clear, colorless solution in pre-filled pen |

## Medical Guidance

Somatropin has profound effects on growth factor signaling, glucose metabolism, and cellular proliferation. It is contraindicated in individuals with active malignancies, proliferative diabetic retinopathy, or acute critical illness. Pre-treatment evaluation must include comprehensive metabolic screening, IGF-1 levels, thyroid function, and cancer screening. GH's diabetogenic effects require monitoring of glucose metabolism, particularly in individuals with pre-diabetes or diabetes risk factors. GH can unmask central hypothyroidism and adrenal insufficiency. Ongoing monitoring of IGF-1, glucose, HbA1c, and thyroid function is essential throughout treatment.

## Frequently Asked Questions

### What is somatropin and how does it differ from GH secretagogues?

Somatropin is recombinant human growth hormone, a 191-amino acid protein identical to pituitary-produced GH. GH secretagogues like CJC-1295/Ipamorelin stimulate the body to produce more of its own GH through hypothalamic/pituitary pathways. Somatropin provides direct GH supplementation, bypassing the pituitary entirely. This means its effects are not limited by individual pituitary capacity, but it also does not maintain the natural pulsatile release pattern.

### What monitoring is required during somatropin use?

Comprehensive monitoring includes IGF-1 levels (the primary dose-titration biomarker), fasting glucose and HbA1c (due to GH's diabetogenic effects), thyroid function (GH affects T4-to-T3 conversion), lipid panel, and periodic cancer screening. IGF-1 should be maintained within the upper-normal age-adjusted reference range. Monitoring intervals are typically every 4-12 weeks during dose titration, with periodic reassessment thereafter.

### Does somatropin require specialist supervision?

Yes. Somatropin has significant effects on growth factor signaling, glucose metabolism, and cellular proliferation that require medical oversight. Comprehensive baseline screening, individualized dose determination based on IGF-1 levels, ongoing metabolic monitoring, and assessment of contraindications are all essential. Self-administration without specialist guidance carries serious health risks.

### What are the effects of growth hormone on glucose metabolism?

Growth hormone promotes lipolysis and fatty acid oxidation, which induces relative insulin resistance by reducing peripheral glucose uptake. In healthy individuals, compensatory insulin secretion maintains normal glucose levels. However, in individuals with pre-existing insulin resistance, impaired glucose tolerance, or diabetes risk factors, GH can worsen glycemic control. Fasting glucose and HbA1c monitoring are essential throughout GH therapy.

### What is somatopause and how does it relate to somatropin?

Somatopause refers to the progressive decline in growth hormone secretion with aging, with mean 24-hour GH output decreasing approximately 14% per decade after age 30. This decline is associated with increased adiposity (particularly visceral fat), decreased lean mass, reduced bone density, and altered body composition. Somatropin supplementation under specialist supervision aims to restore GH levels to counter these age-related changes, guided by IGF-1 monitoring to maintain levels within appropriate ranges.

## Related Compounds

- /compounds/cjc-1295-ipamorelin
- /compounds/tesamorelin
- /compounds/mk-677